Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Pentamethonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.92 |
| ▸ | MEN1 | O00255 | 4/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.92 |
| ▸ | APEX1 | P27695 | 3/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.92 |
| ▸ | LMNA | P02545 | 2/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.92 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.92 |
| ▸ | TSHR | P16473 | 1/20 | 0.92 |
| ▸ | RAB9A | P51151 | 1/20 | 0.92 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.85 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.75 |
| ▸ | APAF1 | O14727 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | RAD52 | P43351 | 1/20 | 0.61 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decamethonium SCHEMBL2125690 | 1.00 | MEN1 (0.92) | MEN1KMT2AACHEAPEX1NFKB1 | |
| Decamethonium SCHEMBL2126026 | 1.00 | MEN1 (0.92) | MEN1KMT2AACHEAPEX1NFKB1 | |
| Hexamethonium SCHEMBL7717613 | 1.00 | MEN1 (0.92) | MEN1KMT2AACHEAPEX1NFKB1 | |
| Decamethonium SCHEMBL2127335 | 1.00 | MEN1 (0.92) | MEN1KMT2AACHEAPEX1NFKB1 | |
| Decamethonium SCHEMBL2128894 | 1.00 | MEN1 (0.92) | MEN1KMT2AACHEAPEX1NFKB1 | |
| Decamethonium SCHEMBL238400 | 0.96 | MEN1 (1.00) | MEN1KMT2AACHEAPEX1NFKB1 | |
| SCHEMBL12126378 | 0.96 | MEN1 (1.00) | MEN1KMT2AACHEAPEX1NFKB1 | |
| SCHEMBL6933263 | 0.96 | MEN1 (1.00) | MEN1KMT2AACHEAPEX1NFKB1 | |
| Pentamethonium SCHEMBL61798 | 0.96 | MEN1 (1.00) | MEN1KMT2AACHEAPEX1NFKB1 | |
| SCHEMBL17898630 | 0.96 | MEN1 (1.00) | MEN1KMT2AACHEAPEX1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150159048-A1 | POLISHING COMPOSITION AND POLISHING METHOD | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150159047-A1 | POLISHING COMPOSITION AND POLISHING METHOD | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-1556029-B1 | THIOMOLYBDATE SALTS AND USES THEREOF | WILSON THERAPEUTICS AB (SE) | 2013-11-27 | — | — | EP | disclosed |
| US-20110151022-A1 | THIOTUNGSTATE ANALOGUES AND USES THEREOF | ATTENUON, LLC | 2011-06-23 | — | — | US | disclosed |
| US-7851505-B2 | Thiotungstate analogues and uses thereof | ATTENUON, LLC (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1556029-A4 | THIOMOLYBDATE ANALOGUES AND USES THEREOF | ATTENUON LLC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7189865-B2 | Thiomolybdate analogues and uses thereof | ATTENUON, LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060160805-A1 | for the treatment of diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or nuclear factor kappa beta dysregulation | ATTENUON, LLC | 2006-07-20 | — | — | US | disclosed |
| EP-1556029-A2 | THIOMOLYBDATE ANALOGUES AND USES THEREOF | Attenuon, LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004110364-A9 | THIOTUNGSTATE ANALOGUES AND USES THEREOF | ATTENUON L L C (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040019087-A1 | Thiomolybdate analogues and uses thereof | ALEXION PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2004009034-A2 | THIOMOLYBDATE ANALOGUES AND USES THEREOF | ATTENUON, LLC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20040019043-A1 | Thiomolybdate analogues and uses thereof | ALEXION PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| EP-0414631-A1 | Auxiliary agent mixture and its use in dyeing polyester fibre materials | CIBA-GEIGY AG (CH) | 1991-02-27 | — | — | EP | disclosed |
| US-4313733-A | Assistant mixture for the dyeing or fluorescent brightening | CIBA-GEIGY CORPORATION (US) | 1982-02-02 | — | — | US | disclosed |
| EP-0014689-A1 | Auxiliary agent and its use in the dyeing or optical bleaching of polyester textile materials | CIBA-GEIGY AG (CH) | 1980-08-20 | — | — | EP | disclosed |
| US-4211527-A | Process for dyeing polyester materials | CIBA-GEIGY CORPORATION (US) | 1980-07-08 | — | — | US | disclosed |
| US-3932189-A | Thermodevelopable photographic material containing high silver ion conducting substance | FUJI PHOTO FILM CO., LTD. (JA) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019043-A1 | Thiomolybdate analogues and uses thereof | FLT4, BMP4, TEK | ACHE 2849/4885MEN1 3943/4885KMT2A 4666/4885 |
| US-20060160805-A1 | for the treatment of diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or nuclear factor kappa beta dysregulation | NFKBIA, RELA, IKBKG | ACHE 2466/4885MEN1 4188/4885KMT2A 3101/4885 |
| US-20040019087-A1 | Thiomolybdate analogues and uses thereof | NFKBIA, NFRKB, NFKB1 | ACHE 2528/4885MEN1 4062/4885KMT2A 4042/4885 |
| US-20110151022-A1 | THIOTUNGSTATE ANALOGUES AND USES THEREOF | NFKBIA, RELA, SLC40A1 | ACHE 2303/4885MEN1 3954/4885KMT2A 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.